Oncolytic Viruses and Immune Checkpoint Inhibitors: The “Hot” New Power Couple
Cancers · 19.08.2023 · 15 (16) · 4178
DOI: 10.3390/cancers15164178 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 19.08.2023. Verfasst von Charlotte Lovatt und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Pancreatic Cancer Research Fund.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) have revolutionized cancer care and shown remarkable efficacy clinically. This efficacy is, however, limited to subsets of patients with significant infiltration of lymphocytes into the tumour microenvironment. To extend their efficacy to patients who fail to respond or achieve durable responses, it is now becoming evident that complex combinations of immunomodulatory agents may be required to extend efficacy to patients with immunologically “cold” tumours. Oncolytic viruses (OVs) have the capacity to selectively replicate within and kill tumour cells, resulting in the induction of immunogenic cell death and the augmentation of anti-tumour immunity, and have emerged as a promising modality for combination therapy to overcome the limitations seen with ICIs. Pre-clinical and clinical data have demonstrated that OVs can increase immune cell infiltration into the tumour and induce anti-tumour immunity, thus changing a “cold” tumour microenvironment that is commonly associated with poor response to ICIs, to a “hot” microenvironment which can render patients more susceptible to ICIs. Here, we review the major viral vector platforms used in OV clinical trials, their success when used as a monotherapy and when combined with adjuvant ICIs, as well as pre-clinical studies looking at the effectiveness of encoding OVs to deliver ICIs locally to the tumour microenvironment through transgene expression.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK.
- Systems Immunity University Research Institute, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK.
ORCID-Profile: Charlotte Lovatt, Alan L Parker
Förderung
- Cancer Research UK
- Pancreatic Cancer Research Fund
Zitieren
APA
Lovatt, C., & Parker, A. L. (2023). Oncolytic Viruses and Immune Checkpoint Inhibitors: The “Hot” New Power Couple. Cancers, 15(16), 4178. https://doi.org/10.3390/cancers15164178
Vancouver
Lovatt C, Parker AL. Oncolytic Viruses and Immune Checkpoint Inhibitors: The “Hot” New Power Couple. Cancers. 2023;15(16):4178. doi:10.3390/cancers15164178
BibTeX
@article{Lovatt2023,
author = {Lovatt, Charlotte and Parker, Alan L},
title = {Oncolytic Viruses and Immune Checkpoint Inhibitors: The “Hot” New Power Couple},
journal = {Cancers},
year = {2023},
volume = {15},
number = {16},
pages = {4178},
doi = {10.3390/cancers15164178}
}
EUVIMED